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Inter- and intratumoral heterogeneity of BCL2 correlates
with IgH expression and prognosis in follicular lymphoma
A Barreca1,13, C Martinengo1,2,13, L Annaratone3,13, L Righi4, A Chiappella5, M Ladetto1, A Demurtas5, L Chiusa5, A Stacchini5,
N Crosetto6,7,8,9,10, A van Oudenaarden6,7,8,9,10 and R Chiarle1,2,11,12
Most follicular lymphomas (FLs) are genetically defined by the t(14;18)(q32;q21) translocation that juxtaposes the BCL2 gene
to the immunoglobulin heavy chain (IgH) 3' regulatory regions (IgH-3'RRs). Despite this recurrent translocation, FL cases are
heterogeneous in terms of intratumoral clonal diversity for acquired mutations and variations in the tumor microenvironment. Here
we describe an additional mechanism that contributes to inter- and intratumoral heterogeneity in FLs. By applying a novel single-
molecule RNA fluorescence-based in situ hybridization (FISH) technique to detect mRNA molecules of BCL2 and IgH in single cells,
we found marked heterogeneity in the number of BCL2 mRNA transcripts within individual lymphoma cells. Moreover, BCL2 mRNA
molecules correlated with IgH mRNA molecules in individual cells both in t(14;18) lymphoma cell lines and in patient samples.
Consistently, a strong correlation between BCL2 and IgH protein levels was found in a series of 205 primary FL cases by flow
cytometry and immunohistochemistry. Inter- and intratumoral heterogeneity of BCL2 expression determined resistance to drugs
commonly used in FL treatment and affected overall survival of FL patients. These data demonstrate that BCL2 and IgH expressions
are heterogeneous and coregulated in t(14;18)-translocated cells, and determine the response to therapy in FL patients.
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INTRODUCTION
Follicular lymphoma (FL) shows a remarkable diversity in
phenotypic, genetic and microenvironment intratumoral hetero-
geneity. Phenotypically, it is well known that FL display striking
inter- and intratumoral heterogeneity in terms of the expression of
several FL markers including immunoglobulin heavy chain (IgH),
CD10, CD20 and BCL2 proteins.1–4 Genetically, copy number
variation and exome sequencing studies have shown marked
intratumoral clonal diversity within the FL.5,6 Analysis of intra-
tumoral clonal diversity within FL cases has shown that the
IgH-BCL2 t(14;18) translocation is a founder event at the top of the
hierarchy of FL oncogenic events, whereas other mutations such
as those in CREBBP, MLL2 and TNFRS14 genes are acquired only by
a fraction of the cells during tumor evolution.6 Similarly, the FL
microenvironment is highly heterogeneous being composed of
stromal cells, macrophages and T/natural killer cell subsets that
surround FL cells, and has roles in FL survival, growth, drug
resistance and prognosis.7–10
The hallmark of almost 90% of FL is the t(14;18)(q32;q21)
translocation that juxtaposes the BCL2 gene to the IgH locus.11
Breakpoints at the BCL2 locus cluster in the major breakpoint
region and in the minor breakpoint region, both regions being
located downstream of the BCL2 gene.12 It is believed that
regulatory elements in the IgH locus, such as enhancers in the
3′ regulatory regions (IgH-3'RRs), have a critical role in the
deregulated expression of the translocated BCL2 allele.13 Indeed,
the IgH-3'RRs increase BCL2 transcription by deregulating promo-
ter usage. In normal cells, BCL2 transcription starts primarily from
the P1 promoter, a TATA-less, GC-rich promoter located ~ 1400 bp
upstream of the translational start site. In t(14;18)-translocated
cells, BCL2 transcription instead originates primarily from the P2
promoter, a classical TATA plus CAAT box promoter located
immediately before the translational start site in exon II.13 When
the IgH-3'RRs are integrated in the BCL2 locus in mice, increased
levels of BCL2 mRNA and protein are observed, and mice develop
FL.14 Overexpression of BCL2 is pivotal for FL and diffuse large
B-cell lymphoma (DLBCL) pathogenesis as it promotes survival of
lymphoma cells.15,16
BCL2 expression shows significant intertumoral variability
among t(14;18)-translocated FLs, ranging from cases with
relatively low to very high expression.16 Furthermore, despite
each FL case carries a clonal t(14;18) translocation that occurs as
an early event in the development of the lymphoma and is
constant among different subclonal populations within each FL
tumor,6 FL shows a large degree of intratumoral heterogeneity of
BCL2 expression, with cells displaying variable amounts of BCL2
within the same tumor.17,18 The molecular basis and the
pathologic implications of such heterogeneity are poorly
understood.
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In this work, we demonstrate that such heterogeneity of BCL2
expression strongly correlates with heterogeneity of IgH expres-
sion, likely due to the activity of IgH-3'RRs that can simultaneously
control BCL2 and IgH transcription in t(14;18) cells. We validated
such correlations by a newly developed single-molecule RNA
fluorescence-based in situ hybridization (smFISH) assay in
individual lymphoma cells and by protein expression in a large
series of FL cases. Importantly, we show that heterogeneity of
BCL2 expression has implications in FL response to therapy and
overall survival.
MATERIALS AND METHODS
Single-molecule RNA FISH
Human IgM+, t(14;18)-positive (SU-DHL-6, Ly8 and VAL) and -negative
(RCK8, MAVER-1, TEKO-1) lymphoma cell lines were cultivated in
RPMI-1640 with 10% fetal bovine serum. Cells were fixed in methanol–
acetic acid (3:1 (vol/vol)), spotted on microscope slides by cytospin, let to
dry and stored at room temperature. Frozen tissue sections (5 μm thick)
were mounted onto a poly-L-lysine-coated coverglass, fixed in 4%
formaldehyde prepared in 1 × phosphate-buffered saline and stored in
70% ethanol at 4 °C.
We designed probes targeting IGHM and BCL2 mRNAs using a
customized algorithm we recently published.19 Probes consisted of the
oligonucleotides listed in Supplementary Table 1. We purchased olig-
onucleotides with a 3′-TEG amino group from Biosearch Technologies
(Novato, CA, USA), and coupled them to either Cy5 (GE Healthcare UK Ltd,
Little Chalfont, Buckinghamshire, UK; cat. no. Q15108) or Alexa Fluor 594
(Molecular Probes, Eugene, OR, USA; cat. no. A20004). We covered cell
spots with 22 × 22mm2 SecureSeal hybridization chambers (Electron
Microscopy Sciences, EMS, Hatfield, PA, USA; cat. no. 70333-10). Before
hybridization, we briefly rehydrated cells by filling the chamber two times
with 100 μl of 2 × saline-sodium citrate buffer (Ambion, Austin, TX, USA;
cat. no. AM9765) supplemented with ribonucleoside–vanadyl complex
(RVC) (NEB, New England Biolabs, Ipswich, MA, USA; cat. no. S1402S)
diluted 1:20 (vol/vol) (saline-sodium citrate-RVC) at room temperature.
Hybridization was performed as we recently described.19 We followed the
same protocol for frozen tissue sections.
Microscopy and analysis
All images were acquired at x100 magnification (oil immersion, high
numerical aperture objective) on an inverted epifluorescence microscope
(Nikon Instruments, Melville, NY, USA) equipped with a high-resolution
CCD camera (Pixis; Princeton Instruments, Trenton, NJ, USA), and
controlled by MetaMorph software (Universal Imaging Corporation,
Downingtown, PA, USA). Per region of interest, we typically acquired an
image stack consisting of five image planes spaced 0.4 μm apart.
Image processing was carried out as previously described.20 Nuclei were
manually segmented and uniformly dilated by 10 pixels (1.25 μm) to
obtain an estimated cell boundary for single-cell mRNA counts assignment.
As cells were not imaged throughout their entire thickness in the z
direction, we computed mRNA densities by dividing single-cell counts by
the volume of the prism with base corresponding to the polygonal
segmentation of a given cell’s nucleus and height equal to 0.4 μm
multiplied by the number of image planes minus one. All data analyses
were performed in MATLAB (The Mathworks, Inc., Natick, MA, USA) using
custom-made scripts.
Case selection and immunohistochemical analysis
Two hundred and five consecutive cases of FL patients with available flow
cytometry data, positivity for the t(14;18) translocation by PCR or FISH and
for BCL2 by immunohistochemistry were selected from the database of the
Surgical Pathology Unit, San Giovanni Battista Hospital of Turin (Turin, Italy)
in the years between 2000 and 2011. The use of samples was approved by
the Internal Ethical Committee. Patients were treated all in the same center
of the San Giovanni Battista Hospital of Turin by multiple cycles of
chemotherapy and rituximab. Cases totally negative for BCL2 by
immunohistochemistry were excluded from the series as potential false
negatives because of the presence of somatic mutations that impair the
recognition of BCL2 by the monoclonal antibody used in the study, as
previously described.21 The immunohistochemical panel included CD3
(1:50), CD5 (1:50), CD10 (1:50; all from Novocastra Lab, Newcastle, UK),
CD20 (1:200), BCL2 (1:30), CD21 (1:30), BCL6 (1:20) and Ki-67 (1:100; all from
Dako, Glostrup, Denmark). Sections of a tonsil with reactive lymphoid
hyperplasia were used for positive and negative controls. Expression of the
positive reaction was evaluated with a three-tie scoring system. FL cases
were considered BCL2high when the intensity of BCL2 staining was higher
than surrounding reactive T and B cells in more than 50% of the FL cells.
BCL2low FL cases had BCL2 staining intensity equal or lower than
surrounding reactive T and B cells in more than 50% of the FL cells.
Immunohistochemistry was performed on all 205 cases. The expression of
BCL2 before and after relapse was investigated in 33 cases.
Flow cytometry
Flow cytometry analysis was conducted on freshly isolated cells obtained
from 156 lymph nodes of FL patients or from reactive lymph nodes as
controls. Isolation, staining and analyses of lymphoid cells have been
previously described.22 Briefly fresh tissues were allocated on saline
solution and mechanically disaggregated with the BD Medimachine
System (BD Biosystems, San Jose, CA, USA). Mononuclear cell suspension
was obtained by the Ficoll-Hypaque density gradient method and
resuspended in RPMI-1640 medium with 10% fetal calf serum. Staining
was performed with directly conjugated monoclonal antibodies in 4-color
(fluorescein isothiocyanate/phycoerythrin/peridinin chlorophyll protein or
peridinin chlorophyll protein-cyanin5.5/allophycocyanin) or 6-color (fluor-
escein isothiocyanate/phycoerythrin/peridinin chlorophyll protein or
peridinin chlorophyll protein–cyanine5.5/phycoerythrin–cyanine7/allophy-
cocyanin/allophycocyanin–H7) combinations. The panels included
antibodies for the screening and for the specific study of B-cell lymphoma
and are indicated in Supplementary Table 2. Antigen expression was
classified as negative, dimly positive, positive and strongly positive using
arbitrary relative linear mean fluorescence intensity cutoff values of 1–5,
5–101, 101–102 and 4102 (data obtained with the FACSCalibur analogical
flow cytometer (BD Biosciences, San Jose, CA, USA): scale range, 100–104)
and of 0–102, 102–103, 103–104 and 4104 (data obtained with the
FACSCantoII digital flow cytometer (BD Biosciences): scale range,
10–264,144), as previously reported.23
For IgH, we considered the expression as low (IgHlow) when it was
negative or dimly positive, and high (IgHhigh) when it was positive or
strongly positive. BCL2 evaluation was performed using a combined
surface and intracellular staining on 156 out the 205 cases of the series
studied by immunohistochemistry. After surface staining and washing,
cells were resuspended, fixed, permeabilized and stained with BCL2-FITC
for 15min at room temperature. For BCL2 expression, the normal ratio of
mean fluorescence intensity of normal B cells versus T cells in reactive
lymph nodes was previously determined in the laboratory to be 1.21+0.18;
an overexpression was considered when a ratio value greater than or equal
to the mean± 2 s.d. was detected.24 A minimum of 20 000 events was
collected for each sample.
In vitro cell treatments and apoptosis detection
Histone deacetylase inhibitor trichostatin A (TSA) and lipopolysaccharide
(LPS) extracted from Escherichia coli O111:B4 (both purchased from Sigma-
Aldrich, St Louis, MO, USA) were resuspended in dimethyl sulfoxide or
phosphate-buffered saline, respectively. For in vitro treatment with drugs,
primary cells freshly obtained from FL patients were cultivated in RPMI-1640
containing 10% heat-inactivated fetal calf serum at 1× 106 cells per ml
concentration for 24 h with 2 μg/ml of doxorubicin or with 2 μg/ml of
rituximab and then stained for intracellular BCL2 and cleaved caspase-3 (Asp
175, 1:200; Cell Signaling, Danvers, MA, USA). The staining for cleaved
caspase-3 was performed using Cell permeabilization buffer (Caltag
Laboratories, Caltag, Burlingame, CA, USA), a secondary biotinylated anti-
rabbit antibody (1:400) and a phycoerythrin-conjugated streptavidin (1:400).
Quantitative RT-PCR and western blotting
For quantitative RT-PCR, total RNA was extracted from 12 cases from cells
or tissue using Trizol according to the instructions of the manufacturers
and 5 μg of RNA were purified with RNeasy Mini Kit (Qiagen, Hilden,
Germany). Reverse transcription-polymerase chain reactions (RT-PCRs)
were performed (1 μg RNA) according to the manufacturer’s protocols
(Invitrogen). Real-time RT-PCR was carried out on a Bio-Rad iCycler using IQ
Sybr Green Supermix (Bio-Rad, Hercules, CA, USA). Bcl-2 was normalized to
RPLP0 housekeeping gene mRNA as described previously. Briefly, to
normalized Bcl-2 mRNA amount we used the formula 2−ΔΔCt, where
ΔCt =Ct (threshold cycle) gene of interest−Ct internal control.25 Primers
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for BCL2 were: 5′-GTCATGTGTGTGGAGAGCGT-3′ and 5′-ACAGTTCCAC
AAAGGCATCC-3′, for RPLP0 were: 5′-GCTTCCTGGAGGGTGTCC-3′ and 5′-GG
ACTCGTTTGTACCCGTTG-3′. For western blotting, total cellular proteins
were extracted from 11 cases and run on a sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, transferred to nitrocellulose, incubated
with the specific antibody (BCL2 1:200 (Dako); α-tubulin 1 (Cell Signaling))
and then detected with peroxidase-conjugated secondary antibodies and
chemiluminescent reagent (ECL; Amersham, GE Healthcare UK Ltd).
Statistical analyses
Correlation between BCL2 and IgH mRNA molecules was statistically
evaluated by Spearman's rank correlation coefficient. The association
between categorical variables, such as patient characteristics, immuno-
globulin expression and BCL2 levels, was estimated by Fisher’s exact test.
Correlations between the mean value of proliferation index (PI),
determined by Ki-67, were calculated using Student’s t test. Po0.05 was
considered statistically significant. The nonparametric Kolmogorov–Smir-
nov test was adopted to compare shift expression of BCL2 and IgM by flow
cytometry. Survival distribution was estimated by the Kaplan–Meier
method. For statistical analysis, overall survival was defined as the interval
between the diagnosis to death or last follow-up visit.
RESULTS AND DISCUSSION
Heterogeneity of BCL2 mRNA correlates with IgH mRNA in t(14;18)
lymphoma cells
In t(14;18) lymphoma cells, the BCL2 wild-type allele is silent and
transcription originates mostly from the BCL2-translocated allele,
where the IgH-3'RRs are thought to regulate the expression of the
BCL2 gene by providing long-range enhancer activity (4350 kb)
and by inducing BCL2 promoter usage shift.13,26 However,
IgH-3'RRs also regulates IgH expression, somatic hypermutation
and class switch in the wild-type IgH allele.27–31 Therefore, we
reasoned that intratumoral heterogeneity of BCL2 expression in
lymphoma cells should at least in part originate from differential
mRNA transcription from the t(14;18)-translocated allele, and
correlate with IgH since both are controlled by IgH-3'RRs regions.
To analyze the BCL2 and IgH mRNA transcripts in single
lymphoma cells, we implemented an smFISH technique that
allows absolute measurements of the number of mRNA molecules
in individual cells.32 For BCL2, we designed arrays of labeled
probes targeting the coding sequence and the 3'-untranslated
region of BCL2 (Figure 1a). For IgH, we designed probes
over the constant region of IgM because it is the most represented
IgH type in FL patients and lymphoma cell lines1 (Figure 1a).
As no true FL cell lines are currently available, we tested the
probes on lymphoma cell lines derived from t(14;18)- translocated
IgM+ DLBCL, and we used IgM+ t(14;18)-negative lymphoma cell
lines as control. To account for differences in cell size, we
computed transcript densities by dividing the number of
transcripts per cell by the cell volume. In all cell lines examined,
we observed a high degree of intratumoral heterogeneity, with
densities ranging from few transcripts (BCL2low or IgMlow) to
several hundred transcripts per 1000 μm3 (BCL2high or IgMhigh)
(Figure 1b). The MAVER-1 cell line showed the highest expression
of both BCL2 and IgM (max density = 647 and 976 per 1000 μm3,
for BCL2 and IgM, respectively) (Figure 1c). Remarkably, we found
a strong correlation between BCL2 and IgM mRNA molecules only
in t(14;18)-translocated cells. In t(14;18)-negative cells, we found
some level of BCL2 and IgH heterogeneity because of intrinsic
gene expression noise and extrinsic factors such as the cell cycle,
but, as expected, we did not find no correlation between BCL2
and IgH mRNA transcripts (Figure 1c). These data indicate that
translocated BCL2 and IgH might be under the same transcrip-
tional control in standard growing condition. Next, we wanted to
test whether BCL2 and IgM mRNA molecules correlated also in
primary samples from FL patients by probing frozen sections
obtained from freshly isolated FL cases. In all the cases analyzed
(n= 5), we found a significant correlation between BCL2 and IgH
mRNA molecules, thus indicating that BCL2 and IgH are
coregulated not only in lymphoma cell lines but also in FL
patients (Figure 1d).
IgH-3'RRs have been shown to physically and functionally
interact at long distance with the translocated BCL2 promoter
region through transcription factors such as the POU2 family
transcription factor Oct-2 and its co-factor Bob-1.33,34 Treatment
with the histone deacetylase inhibitor TSA decreases BCL2
transcription from both the P1 and P2 promoters by decreasing
Oct-2 protein levels and by reducing Oct-2 binding to BCL2
promoters.34 Also, TSA treatment impairs Oct-2 binding to
IgH-3'RRs, thereby further repressing BCL2 transcription by
blocking the interaction between BCL2 promoters and IgH-3'
RRs.34 In this context, we reasoned that TSA treatment should
simultaneously affect BCL2 and IgH mRNA levels with a more
profound effect on BCL2 expression in t(14;18)-translocated
lymphoma cells than in control cells, because of the disruption
of the interaction between the BCL2 promoters and the IgH-3'RRs.
Indeed, using quantitative PCR we found that treatment with TSA
induced a significantly stronger reduction of BCL2 transcription in
t(14;18) translocation positive than in translocation-negative
lymphoma cells in which there is no interaction with the IgH-3'RRs,
and the BCL2 transcription originates mainly from the P1 promoter
(Figure 2a). As expected, the decrease of BCL2 transcription was
accompanied by a decrease in IgM expression (Figure 2b). In
contrast, when we treated lymphoma cells with LPS to increase
IgH transcription by enhancing the effects of the IgH-3'RRs,35 we
observed an increase of both IgH and BCL2 expressions in t(14:18)-
translocated lymphoma cells, whereas translocation-negative
lymphoma cells upregulated IgM levels but showed no changes
in BCL2 transcription (Figures 2c and d). In conclusion, all these
data indicate that IgH and BCL2 expression are coregulated in
t(14;18) lymphoma cell lines likely because they are under the
same transcriptional control if the IgH-3'RRs.
Heterogeneous BCL2 expression correlates with IgH expression in
FL patients
To extend these findings to primary FL patients, we characterized
BCL2 and IgH protein expression levels in a series FL cases by flow
cytometry and immunohistochemistry. To determine the intensity
of BCL2 expression in FL by flow cytometry, we compared control
reactive lymph nodes with lymph nodes obtained from FL patients.
In reactive lymph nodes, flow cytometry showed that the
intracytoplasmic expression of BCL2 was comparable in CD10− B
cells and T cells according to the criteria indicated in Materials and
methods. As expected, reactive CD10+ B cells from germinal centers
showed lower BCL2 expression. In lymph nodes from FL patients,
when the expression of BCL2 in the CD10+ B-cell clonal tumoral
population was higher than in T cells or CD10− B cells, we
considered the case as BCL2high. In contrast, when the tumoral
population showed intensity comparable or lower than reactive
T cells, we considered the case as BCL2low. We then validated this
classification into BCL2high and BCL2low FL cases by immunohisto-
chemistry on all the cases by staining with anti-BCL2 antibody on
formalin-fixed, paraffin-embedded sections. We translated the
criteria defined by flow cytometry, and considered the FL cases
as BCL2high or BCL2low when the intensity of BCL2 expression in the
neoplastic follicles was higher or lower/equal to the surrounding
reactive T and B cells, respectively (Figures 3A–C). We analyzed 156
cases by flow cytometry and 205 cases by immunohistochemistry.
By these criteria, the concordance between flow cytometry and
immunohistochemistry was very high (Fisher’s exact test:
Po0.0001, Supplementary Table 3) allowing us to use immuno-
histochemistry as a reliable technique to quantitate BCL2 expres-
sion on the entire series. As a confirmation of the validity of such
approach, FL cases classified as BCL2high by immunohistochemistry
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Figure 1. Heterogeneity of BCL2 mRNA expression and correlation with IgM mRNA molecules in cells with t(14:18). (a) Schematic
representation of smFISH for BCL2 and IgM. Single-fluorophore- (magenta, BCL2; green, IgM) labeled 20 nt oligonucleotides target the coding
(CDS) and 3′-untranslated region (3′-UTR) BCL2 and IgM transcripts. For IgM, the oligonucleotides were designed in the constant region (IgM
C); IgM V, IgM variable region; (b) BCL2 transcripts (red spots) and IgM transcripts (green spots) were detected within single cells. Images of
single lymphoma cells are representative of different patterns of BCL2 and IgM expression. (c) BCL2 vs IgM expression in single cells of
lymphoma cells lines carrying the translocation t(14;18)- (top) compared with t(14;18)-negative lymphoma cells (bottom); n, number of single
cells counted; r, Spearman's rank correlation coefficient. (d) BCL2 vs IgM expression in single cells of FL patients carrying the t(14;18)
translocation. Frozen sections from IgM+ FL patients were incubated with BCL2 and IgM probes. BCL2 and IgM mRNA molecules were counted
as indicated in the Material and methods section and plotted in colorimetric scale.
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Figure 2. BCL2 and sIgH show coordinated stimulation-induced changes. To modulate the activity of the IgH-3′RRs, t(14;18)-positive
lymphoma cells SU-DHL-6 and Ly8 and t(14;18)-negative RCK8 were treated for 1 h with 500 ng/ml. TSA diluted from a stock solution in
dimethyl sulfoxide (DMSO). (a) BCL2 mRNA levels were determined by quantitative real-time RT-PCR during TSA treatment. For each
condition, BCL2 mRNA levels were normalized to the expression of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) housekeeping
gene. Fold changes in BCL2 mRNA expression were calculated by comparing TSA-treated cells to control cells. Standard deviations and
statistics were calculated from three independent experiments. **Po0.01. (b) Intensities of surface IgM (sIgM) immunoglobulin expression
(sIgM) were measured by flow cytometry (black, unstained control; red, control DMSO-treated cells; green, TSA-treated cells). P-value was
calculated using the nonparametric Kolmogorov–Smirnov test to compare shifted IgM expression. (c) t(14;18)-positive SU-DHL-6 and
-negative RCK8 lymphoma cells were stimulated for 24 or 48 h with 1 μg/ml LPS and flow cytometry for sIgM was performed as described.
P-value was calculated using the nonparametric Kolmogorov–Smirnov test to compare shifted IgM expression. (d) BCL2 mRNA levels were
determined by quantitative real-time RT-PCR at the indicated time point of LPS treatment. For each condition, BCL2 mRNA levels were
normalized to the expression of the GAPDH housekeeping gene. Fold changes in BCL2 mRNA expression were calculated by comparing
LPS-treated to control cells. Standard deviations and statistics were calculated from three independent experiments. **Po0.01.
BCL2 heterogeneity in follicular lymphoma
A Barreca et al
5
© 2014 Macmillan Publishers Limited Blood Cancer Journal
showed significantly higher levels of BCL2 mRNA (Figure 3D) and
BCL2 protein (Figures 3E and F) as compared with BCL2low cases.
IgH expression was evaluated by flow cytometry in all 205 cases
and considered low (IgHlow) or high (IgHhigh) as described in
Materials and methods. When more than one IgH was expressed,
we scored the IgH IgM, IgG, IgD or IgA that was expressed by the
majority of lymphoma cells. By these criteria, 179 cases (87.3%)
showed high levels of surface IgH expression (sIgHhigh), whereas
26 cases (12.7%) had low expression (sIgHlow) (Table 1). Among
sIgHhigh cases, we found 129 (72.1%) BCL2high and only 50 (27.9%)
BCL2low FL cases, whereas sIgHlow cases were mostly BCL2low
(9 BCL2high vs 17 BCL2low; Fisher’s exact test: Po0.0001) (Table 1).
BCL2 expression was not skewed toward any IgH subclasses as a
similar distribution of BCL2high and BCL2low cases was observed in
the different IgH subtypes (Table 1). A strong correlation between
IgH and BCL2 expression was also found when we scored both IgH
and BCL2 expression by flow cytometry, although the series of
cases was smaller (156 cases; Supplementary Table 4). Therefore,
these data demonstrate that a strong correlation between IgH and
BCL2 expression is found also at protein levels in a large series of
primary FL patients.
FL cases are typically divided into three main histologic grades
based on the relative proportion of centrocytes and centroblasts.1
Grade 1 and 2 FL cases are predominantly composed of
centrocytes with low proliferation rates, whereas grade 3 FL cases
(which are further subdivided into grades 3a and 3b) have
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Figure 3. Intertumoral heterogeneous BCL2 expression in FL cases by immunohistochemistry, flow cytometry, mRNA and western blot. (A and B)
Representative cases of FL patients with either sIgHhigh/BCL2high (A) or sIgHlow/BCL2low (B) expression. Surface IgM (sIgM) and intracellular
BCL2 expression were detected as described in Materials and methods. Intensity of expression was considered high (red square) for IgH and
BCL2 when the mean intensity was higher than 102 FI. Green lines represent negative controls for the staining. (C) We stained formalin-fixed
and paraffin-embedded sections from FL cases with the following primary antibodies: BCL2 (a and e), CD10 (b and f), CD20 (c and g) and Ki-67
(d and h). (a–d) Grade 2 BCL2high FL case in which the intensity of BCL2 expression in FL cells was higher than reactive T cells; (e–h) grade 2
BCL2low FL case with BCL2 expression lower than normal reactive cells. Microphotographs were taken with an Olympus BX51WI microscope
with a x10 objective. (D) BCL2 mRNA levels in patients with high or low BCL2 expression as determined by immunohistochemistry. All cases
were selected to have 470% neoplastic FL cells by flow cytometry stainings. BCL2 mRNA levels were analyzed by quantitative RT-PCR in
purified cases classified as BCL2high or BCL2low based on immunohistochemistry. Expression of BCL2 mRNA was normalized to the expression
of RPLP0 housekeeping gene. Control cell lines analyzed were either t(14;18)-positive (DHL-6, circle; Ly8, triangle) or t(14;18)-negative (Ly3,
diamond; RCK8, square). (E and F) BCL2 protein levels in patients with BCL2 high or low expression. For western blot, we selected FL cases
classified as BCL2high or BCL2low based on immunohistochemistry that had 470% neoplastic cells. Cells were lysed and western blot was
performed with the indicated antibodies. The ratio of BCL2 and tubulin band intensities measured by densitometry in FL cases were
calculated and expressed as a relative number to the t(14;18)-translocated VAL cell line that was used as a standard. (f ) Histograms represent
mean intensities (± s.d.) for BCL2high and BCL2low cases shown in (g) and calculated as relative expression to the VAL control cell line. *Po0.05
BCL2 heterogeneity in follicular lymphoma
A Barreca et al
6
Blood Cancer Journal © 2014 Macmillan Publishers Limited
increasing numbers of actively proliferating centroblasts with
higher proliferation rates.1 As previous reports showed an inverse
correlation between proliferation rates and BCL2 expression,2,36
we asked whether heterogeneity of BCL2 expression in our tumor
cohort was independent of the proliferation rates of the tumor
cells. To this end, we first measured the PI in all FL patient samples
by staining with the proliferation marker Ki-67 (Figure 3C) and
found, as expected, that grade 1 and 2 FL showed a lower mean PI
as compared with grade 3a and 3b FL (20.08% for grades 1 and 2
vs 39.22% for grade 3a vs 56.8% for grade 3b). Overall, BCL2
expression inversely correlated with the PI, as suggested by
previous studies on BCL2 expression and proliferation in FL cells 2,36
(Supplementary Table 5). When we correlated BCL2 expression
and FL grading, we found that grade 1 and 2 FL more frequently
showed BCL2high expression as compared with grade 3 FL
(Table 1). Given the different rates of PI between grade 1 and 2
and grade 3 FL, we next wondered whether the correlation of
BCL2 expression with IgH could be still detected regardless of the
grading and proliferation rate. To this end, we repeated our
analysis in low proliferating grade 1 and 2 FL cases, and found a
distribution of BCL2high and BCL2low cases similar to the whole
series, together with a conserved strong correlation between sIgH
and BCL2 expression (Table 2). Therefore, these analyses support
the conclusion that the correlation between IgH and BCL2
expression is not only independent of the proliferation rate, as
suggested by the smFISH data, but also of the FL grade. Despite a
similar trend, a statistical correlation was not observed between
IgH and BCL2 expression in grade 3 FL, possibly because of the
relatively low number of cases analyzed or to a different biology of
grade 3 FL, which typically have an increased number and
complex genetic aberrations as compared with grade 1 and 2 FL.37
Heterogeneity of BCL2 expression in individual FL cases
determines resistance to therapy
We showed that FL cases exhibit inter- and intratumoral
heterogeneity of BCL2 expression that correlates with IgH both
at the transcription and protein levels. As BCL2 levels in FL cells
are critical to protect lymphoma cells from apoptosis, we then
asked whether this heterogeneity would have therapeutic and
prognostic impact. To this end, we first characterized resistance to
therapy of FL cells from individual FL patients, to limit the
confounding effect of variations in the genetic background
among different FL cases. We studied by flow cytometry individual
FL cases for BCL2 and IgH expression, and showed that, by gating
on the CD19+CD10+ monoclonal lymphoma population, BCL2high
cells were mostly sIgHhigh, whereas BCL2low cells were mostly
sIgHlow (Figures 4a–c). Therefore, BCL2high and BCL2low cell
populations could be detected in the same neoplastic clone in
individual FL patients, and correlated with IgH expression.
Next, we compared the response to therapy of such BCL2high
and BCL2low cell populations. We treated freshly isolated FL cells
with doxorubicin or with rituximab, which are commonly used in
Table 1. Patient characteristics, immunoglobulin expression and Bcl-2 levels
Category Total population BCL2high BCL2low P-value
No. of patients % No. of patients % No. of patients %
Sex
Male 101 49.3 67 66.3 34 33.7 χ2= 0.021, P= 0.882
Female 104 50.7 71 68.3 33 31.7 P= 0.882
Age (years)
Median 61 61 62
Range 26–89 26–89 32–86
IgH surface levels
sIgHhigh 179 87.3 129 72.1 50 27.9 χ2= 12.821, Po0.0001
sIgHlow 26 12.7 9 34.6 17 65.4 Po0.0001
IgH subtype
IgM 106 51.7 68 64.2 38 35.8 χ2= 1.243, P= 0.743
IgG 88 42.9 62 70.5 26 29.5 P= 0.743
IgA 6 2.9 4 66.7 2 33.3
IgD 5 2.4 4 80 1 20
FL grading
Grades 1 and 2 139 67.8 103 74.1 36 25.9 χ2= 9.388, P= 0.009
Grade 3a 51 24.9 28 54.9 23 45.1 P= 0.009
Grade 3b 15 7.3 7 46.7 8 53.3
IgH expression levels and subtypes were determined by flow cytometry. BCL2 expression intensities were scored by immunohistochemistry. BCL2 expression
was considered high when higher than the expression in surrounding normal and reactive cells T cells, and low when similar or lower than surrounding
normal and reactive cells T cells. Abbreviations:FL, follicular lymphoma; Ig, immunoglobulin; sIg, surface Ig.
Table 2. Correlation between sIgH and BCL2 expression in FL different
grades
Total
population
BCL2high BCL2low P-value
(Fisher’s exact
test)
No. of
patients
% No. of
patients
% No. of
patients
%
Grades 1 and 2
sIgHhigh 123 88.5 97 78.8 26 21.2 P= 0.001
sIgHlow 16 11.5 6 37.5 10 62.5
Grade 3
sIgHhigh 56 84.8 32 57.1 24 42.9 P= 0.17
sIgHlow 10 15.2 3 30 7 70
Abbreviations: FL, follicular lymphoma; Ig, immunoglobulin; sIg, surface Ig.
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FL therapy, and measured drug-induced Caspase 3 activation in
BCL2high and BCL2low populations. In these conditions, BCL2high FL
cells showed significantly higher resistance to treatment-induced
apoptosis than BCL2low FL cells, thus indicating a differential
sensitivity to therapy of distinct sub-populations of FL cells in
individual patients (Figures 4d and e).
A prediction stemming from this observed differential sensitiv-
ity to therapy between BCL2high and BCL2low populations in FL
cases is that BCL2high cells would be progressively enriched over
time in treated FL patients. To test this hypothesis, we evaluated
BCL2 expression at diagnosis and at relapse after chemotherapy
and rituximab treatment in 33 FL patients for which sequential
biopsies were available. Strikingly, all the 19 FL cases with BCL2high
expression at diagnosis retained high expression after therapy,
whereas 11/14 (78%) BCL2low cases showed a BCL2high expression
at relapse (Figure 4f), suggesting that BCL2high FL cells are
progressively selected during therapy.
To further study the therapeutic implications of BCL2 hetero-
geneity in terms of resistance to therapy, we sought to determine
whether BCL2 levels could also have prognostic implications and
determine survival in FL patients. To this end, we analyzed the
overall survival of BCL2high or BCL2low FL patients in our series. Out
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of the 205 cases in the series, we included in the survival analyses
all patients (n= 103) for which a minimum follow-up of 5 years
was available. All patients were treated with regimens of
chemotherapy and rituximab, and clinical characteristics were
evaluated in this series including involvement of bone marrow
and extranodal sites, Ann Arbor stages, presence of B symptoms,
International Prognostic Index), Follicular Lymphoma International
Prognostic Index (FLIPI) and FLIPI-2 (ref. 38) (Supplementary Table 6).
Remarkably, BCL2low cases had a significantly higher probability of
survival as compared with BCL2high cases (Figure 4g). A recent
work by Maeshima et al.39 analyzed BCL2 expression by
immunohistochemistry in a series of FL and found 60% of FL
cases as BCL2high, very similar to our rate of 67% (Table 1). They
also found an inverse correlation between FL grade and BCL2
expression, very similar to our findings (Table 1). However, the
authors did not report a significant association between Bcl-2
expression and disease outcome. In our series, together with BCL2
expression levels, other clinicopathologic features showing
significance by univariate analysis were FLIPI, FLIPI-2 and the
Ann Arbor stage. However, when we performed multivariate Cox
proportional hazard analyses using the significant parameters
emerging from the univariate analysis, the only independent
prognostic factor for disease-free survival and overall survival was
FLIPI-2 (disease-free survival: hazard ratio: 2.61; 95% confidence
interval: 1.399–4.868; P= 0.003; overall survival: hazard ratio: 9.381;
95% confidence interval: 1.975–44.553; P= 0.005).
In conclusion, in this study we provide evidence for concurrent
regulation of IgH and BCL2 that determines BCL2 heterogeneous
expression in FL cells with implications for the biology and the
therapy of FL. We suggest that the coregulation of IgH and BCL2 is
mediated by the shared IgH-3'RRs (Figure 4h). The factors and
mechanisms involved in the interaction of IgH-3'RRs with the BCL2
promoter are complex and still poorly characterized. Taken
together with Oct1-2 and Bob-1 discussed above, other transcrip-
tion factors such as c/EBPα, Sp1, A-Myb and the NF-kB pathway
can regulate this physical interaction and, thereby, BCL2 transcrip-
tion in the t(14;18)-translocated allele.33,40,41 In this context, it is
conceivable that drugs or different stimuli from the microenviron-
ment, such as growth factors and cytokines, could change the
availability or the balance between these transcription factors and
thus modify IgH and BCL2 expression in FL cells. It is possible that
the important role of the tumor microenvironment in FL
pathogenesis and prognosis7,8,42 could partially be explained
though the modulation of IgH and BCL2 expression.
Finally, a similar coregulation could also explain heterogeneity
of oncogene expression in other types of lymphoma where
different oncogenes are involved in chromosomal translocations
with the IgH locus.43 As examples, mantle cell lymphoma is
genetically characterized by the t(11;14) translocation that
juxtaposes the Cyclin D1/CCND1 gene to the IgH locus,1 whereas
DLBCL carry BCL6/IgH translocations in about 30% of the cases.44
Cyclin D1 expression in mantle cell lymphoma and BCL6
expression in DLBCL are quite heterogeneous45 and might as
well correlate with IgH expression as we showed for BCL2 and IgH
in FL. Similarly, in Burkitt’s lymphoma c-myc is translocated with
IgH and its expression is under the control of IgH-3'RRs.46
Importantly, heterogeneous oncogene expression in sub-
populations of mantle cell lymphoma, DLBCL and Burkitt’s
lymphoma could have an important role in the response to
therapy and prognosis. Thus, the pharmacologic or genetic
disruption of the binding of IgH-3'RRs to the BCL2 promoter, as
to other oncogene promoters, could result in decreased oncogene
transcription, and might therefore be exploited as a novel
therapeutic tool in lymphoma.
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Figure 4. Intratumoral heterogeneity of BCL2 expression correlates with sIgH expression. (a and b) Levels of sIgH correlate with BCL2 protein
expression within the neoplastic population derived from single FL patients. (a) Dot plot from one representative sIgM+ FL patient stained by
flow cytometry with the indicated antibodies. Cells were freshly isolated from lymph nodes and the neoplastic clone was identified and gated
by CD19, CD10 and Ig light-chain restriction. (b) Within the neoplastic population, cells with sIgHlow (green dots) or sIgHhigh (blue dots)
expression were gated and studied for intracellular BCL2 expression. P-value was calculated using the nonparametric Kolmogorov–Smirnov
test to compare the shift in BCL2 expression. (c) Histograms represent the mean± s.d. fluorescence intensities for BCL2 surface expression
analyzed by flow cytometry in the sub-populations of sIgHhigh and sIgHlow cells in individual FL cases. Ten cases were analyzed; **Po0.01
(d and e) Differential sensitivity to therapeutic agents of BCL2high and BCL2low populations of FL cells within the same FL patient. Cells were
freshly isolated from patients with 470% neoplastic population and cultivated with either 2 μg/ml of doxorubicin (top panels) or 2 μg/ml of
rituximab (bottom panels). After 24 h, cells were stained with CD10 to identify the neoplastic cells, fixed and permeabilized to stain
intracellular BCL2 and cleaved caspase-3 to detect apoptotic cells. Percentages of apoptotic cells (cleaved caspase-3 positive) in the CD10+
/BCL2high or CD10+/BCL2low gate are indicated. (e) Mean percentages and standard deviations of cells showing cleaved caspase-3 induced by
the indicated treatment in selective CD10+/BCL2high or CD10+/BCL2low tumor populations from eight cases of FL. **Po0.01. (f) The expression
levels of BCL2 were characterized by immunohistochemistry in 33 FL cases with available biopsy before treatment and after relapse. All the
BCL2high cases maintained a high expression at relapse, with no case showing a decreased BCL2 expression. In contrast, 11/14 cases with
BCL2low expression at diagnosis showed a BCL2high expression at the relapsed biopsy. (g) Overall survival for patients (n= 102) with BCL2low
expression (blue) and for patients with BCL2high expression (green) (P= 0.03). (h) Schematic representation of the model of coregulation of IgH
and BCL2 expression in FL. In t(14;18)-translocated cells, the BCL2 gene is juxtaposed to the IgH locus. Typically, chromosomal breakpoint are
located in the V(d)J region of the IgH locus and 3′ downstream of the BCL2 gene. As a result, the BCL2 gene is under the control of regulatory
sequences located in the IgH locus, mainly the IgH-3'RRs. The IgH-3′RRs physically interact with the IgH promoters to induce IgH expression in
the normal allele, and with the BCL2 promoter regions in the translocated allele. The IgH-3′RRs upregulate BCL2 transcription by a switch in
the usage from the P1 to the P2 promoter. Stimuli from the microenvironment or modifications of endogenous transcription factors that act
via the IgH-3′RRs could coregulate both the transcription levels of the IgH locus and the translocated BCL2 locus, thus inducing changes in
protein expression levels.
BCL2 heterogeneity in follicular lymphoma
A Barreca et al
9
© 2014 Macmillan Publishers Limited Blood Cancer Journal
REFERENCES
1 Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classifi-
cation of Tumors of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC
Press, 2008.
2 Masir N, Campbell LJ, Goff LK, Jones M, Marafioti T, Cordell J et al. BCL2 protein
expression in follicular lymphomas with t(14;18) chromosomal translocations.
Br J Haematol 2009; 144: 716–725.
3 Camacho FI, Bellas C, Corbacho C, Caleo A, Arranz-Saez R, Cannata J et al.
Improved demonstration of immunohistochemical prognostic markers for
survival in follicular lymphoma cells. Mod Pathol 2011; 24: 698–707.
4 Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration
of surface antigen expression in common B-cell malignancies using flow
cytometry. Immunol Invest 2006; 35: 93–114.
5 Eide MB, Liestol K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L et al.
Genomic alterations reveal potential for higher grade transformation in follicular
lymphoma and confirm parallel evolution of tumor cell clones. Blood 2010; 116:
1489–1497.
6 Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL et al. Hierarchy in somatic
mutations arising during genomic evolution and progression of follicular
lymphoma. Blood 2013; 121: 1604–1611.
7 Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al. Prediction of
survival in follicular lymphoma based on molecular features of tumor-infiltrating
immune cells. N Engl J Med 2004; 351: 2159–2169.
8 Ame-Thomas P, Tarte K. The yin and the yang of follicular lymphoma cell niches: Role
of microenvironment heterogeneity and plasticity. Semin Cancer Biol 2013; 24: 23–32.
9 Gribben JG. Implications of the tumor microenvironment on survival and disease
response in follicular lymphoma. Curr Opin Oncol 2010; 22: 424–430.
10 Gribben J, Rosenwald A, Gascoyne R, Lenz G. Targeting the microenvironment.
Leuk Lymphoma 2010; 51(Suppl 1): 34–40.
11 Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in
human follicular lymphoma. Science 1985; 228: 1440–1443.
12 Cleary ML, Galili N, Sklar J. Detection of a second t(14;18) breakpoint cluster
region in human follicular lymphomas. J Exp Med 1986; 164: 315–320.
13 Duan H, Heckman CA, Boxer LM. The immunoglobulin heavy-chain gene 3'
enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells. Oncogene
2007; 26: 2635–2641.
14 Xiang H, Noonan EJ, Wang J, Duan H, Ma L, Michie S et al. The immunoglobulin
heavy chain gene 3' enhancers induce Bcl2 deregulation and lymphomagenesis
in murine B cells. Leukemia 2011; 25: 1484–1493.
15 Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the
bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia
cell lines. Ann Oncol 1994; 5(Suppl 1): 61–65.
16 Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest
2012; 122: 3424–3431.
17 Gaulard P, d'Agay MF, Peuchmaur M, Brousse N, Gisselbrecht C, Solal-Celigny P
et al. Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol
1992; 140: 1089–1095.
18 Dogan A, Du MQ, Aiello A, Diss TC, Ye HT, Pan LX et al. Follicular lymphomas
contain a clonally linked but phenotypically distinct neoplastic B-cell population
in the interfollicular zone. Blood 1998; 91: 4708–4714.
19 Semrau S, Crosetto N, Bienko M, Boni M, Bernasconi P, Chiarle R et al. FuseFISH:
robust detection of transcribed gene fusions in single cells. Cell Rep 2014; 6:
18–23.
20 Itzkovitz S, Lyubimova A, Blat IC, Maynard M, van Es J, Lees J et al. Single-molecule
transcript counting of stem-cell markers in the mouse intestine. Nat Cell Biol 2012;
14: 106–114.
21 Schraders M, de Jong D, Kluin P, Groenen P, van Krieken H. Lack of Bcl-2
expression in follicular lymphoma may be caused by mutations in the BCL2 gene
or by absence of the t(14;18) translocation. J Pathol 2005; 205: 329–335.
22 Demurtas A, Aliberti S, Bonello L, Di Celle PF, Cavaliere C, Barreca A et al.
Usefulness of multiparametric flow cytometry in detecting composite lymphoma:
study of 17 cases in a 12-year period. Am J Clin Pathol 2011; 135: 541–555.
23 Barrena S, Almeida J, Del Carmen Garcia-Macias M, Lopez A, Rasillo A, Sayagues JM
et al. Flow cytometry immunophenotyping of fine-needle aspiration specimens:
utility in the diagnosis and classification of non-Hodgkin lymphomas.
Histopathology 2011; 58: 906–918.
24 Demurtas A, Stacchini A, Aliberti S, Chiusa L, Chiarle R, Novero D. Tissue
flow cytometry immunophenotyping in the diagnosis and classification of
non-Hodgkin's lymphomas: a retrospective evaluation of 1,792 cases. Cytometry
Part B 2013; 84: 82–95.
25 Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C
(T) method. Nat Protocols 2008; 3: 1101–1108.
26 Heckman CA, Cao T, Somsouk L, Duan H, Mehew JW, Zhang CY et al. Critical
elements of the immunoglobulin heavy chain gene enhancers for deregulated
expression of bcl-2. Cancer Res 2003; 63: 6666–6673.
27 Pinaud E, Marquet M, Fiancette R, Peron S, Vincent-Fabert C, Denizot Y et al.
The IgH locus 3' regulatory region: pulling the strings from behind. Adv Immunol
2011; 110: 27–70.
28 Vincent-Fabert C, Fiancette R, Cogne M, Pinaud E, Denizot Y. The IgH 3' regulatory
region and its implication in lymphomagenesis. Eur J Immunol 2010; 40:
3306–3311.
29 Cogne M, Lansford R, Bottaro A, Zhang J, Gorman J, Young F et al. A class switch
control region at the 3' end of the immunoglobulin heavy chain locus. Cell 1994;
77: 737–747.
30 Pinaud E, Khamlichi AA, Le Morvan C, Drouet M, Nalesso V, Le Bert M et al.
Localization of the 3' IgH locus elements that effect long-distance regulation of
class switch recombination. Immunity 2001; 15: 187–199.
31 Rouaud P, Vincent-Fabert C, Saintamand A, Fiancette R, Marquet M, Robert I et al.
The IgH 3' regulatory region controls somatic hypermutation in germinal center
B cells. J Exp Med 2013; 210: 1501–1507.
32 Raj A, van den Bogaard P, Rifkin SA, van Oudenaarden A, Tyagi S. Imaging
individual mRNA molecules using multiple singly labeled probes. Nat Methods
2008; 5: 877–879.
33 Heckman CA, Duan H, Garcia PB, Boxer LM. Oct transcription factors mediate
t(14;18) lymphoma cell survival by directly regulating bcl-2 expression. Oncogene
2006; 25: 888–898.
34 Duan H, Xiang H, Ma L, Boxer LM. Functional long-range interactions of the IgH 3'
enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells. Oncogene
2008; 27: 6720–6728.
35 Gordon SJ, Saleque S, Birshtein BK. Yin Yang 1 is a lipopolysaccharide-inducible
activator of the murine 3' Igh enhancer, hs3. J Immunol 2003; 170: 5549–5557.
36 Winter JN, Andersen J, Reed JC, Krajewski S, Variakojis D, Bauer KD et al. BCL-2
expression correlates with lower proliferative activity in the intermediate- and
high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group
and Southwest Oncology Group cooperative laboratory study. Blood 1998; 91:
1391–1398.
37 Leich E, Ott G, Rosenwald A. Pathology, pathogenesis and molecular genetics of
follicular NHL. Best Pract Res Clin Haematol 2011; 24: 95–109.
38 Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U et al.
Follicular Lymphoma International Prognostic Index 2: a new prognostic index
for follicular lymphoma developed by the International Follicular Lymphoma
Prognostic Factor Project. J Clin Oncol 2009; 27: 4555–4562.
39 Maeshima AM, Taniguchi H, Nomoto J, Miyamoto K, Fukuhara S, Munakata W
et al. Prognostic implications of histologic grade and intensity of Bcl-2 expression
in follicular lymphomas undergoing rituximab-containing therapy. Hum Pathol
2013; 44: 2529–2535.
40 Heckman CA, Mehew JW, Boxer LM. NF-kappaB activates Bcl-2 expression in
t(14;18) lymphoma cells. Oncogene 2002; 21: 3898–3908.
41 Heckman CA, Mehew JW, Ying GG, Introna M, Golay J, Boxer LM. A-Myb
up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. J Biol
Chem 2000; 275: 6499–6508.
42 de Jong D, Fest T. The microenvironment in follicular lymphoma. Best Pract Res
Clin Haematol 2011; 24: 135–146.
43 Gostissa M, Alt FW, Chiarle R. Mechanisms that promote and suppress chromo-
somal translocations in lymphocytes. Annu Rev Immunol 2011; 29: 319–350.
44 Basso K, Dalla-Favera R. BCL6: master regulator of the germinal center reaction
and key oncogene in B cell lymphomagenesis. Adv Immunol 2010; 105: 193–210.
45 Klapper W. Histopathology of mantle cell lymphoma. Semin Hematol 2011; 48:
148–154.
46 Gostissa M, Yan CT, Bianco JM, Cogne M, Pinaud E, Alt FW. Long-range oncogenic
activation of Igh-c-myc translocations by the Igh 3' regulatory region. Nature
2009; 462: 803–807.
This work is licensed under a Creative Commons Attribution-
NonCommercial-ShareAlike 4.0 International License. The images or
other third party material in this article are included in the article’s Creative Commons
license, unless indicatedotherwise in the credit line; if thematerial is not included under
the Creative Commons license, users will need to obtain permission from the license
holder to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-sa/4.0/
Supplementary Information accompanies this paper on Blood Cancer Journal website (http://www.nature.com/bcj)
BCL2 heterogeneity in follicular lymphoma
A Barreca et al
10
Blood Cancer Journal © 2014 Macmillan Publishers Limited
